In vivo immunomodulatory effect and safety of MSC-derived secretome [version 2; peer review: 2 not approved]

Background: Secretomes have been gaining interest in treating several diseases due to their pharmaceutical effects, such as the immunomodulatory effect. This study aimed to determine the immunomodulatory effect of secretomes derived from human umbilical cord mesenchymal stem cells (MSCs) and their s...

Full description

Saved in:
Bibliographic Details
Published in:F1000 research 2023, Vol.12, p.421
Main Authors: Agung Nugrahaningsih, Dwi Aris, Purwadi, Purwadi, Sarifin, Is, Bachtiar, Indra, Sunarto, Sunarto, Ubaidillah, Ubaidillah, Larasati, Ines, Satriyo, Pamungkas Bagus, Setiasari, Dicka Wahyu, Hasanah, Maria Nur, At-thobari, Jarir, Mubarika, Sofia
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Secretomes have been gaining interest in treating several diseases due to their pharmaceutical effects, such as the immunomodulatory effect. This study aimed to determine the immunomodulatory effect of secretomes derived from human umbilical cord mesenchymal stem cells (MSCs) and their safety. Methods: We conducted an in vivo immunomodulatory study using a carbon clearance assay. The safety of single-dose administration of secretome was done using fixed-dose methods of acute toxicity test. Results: The phagocytic index was higher in mice treated with secretome than in untreated mice. The acute toxicity study also showed that the administration of secretome derived from human umbilical cord MSCs did not change the mice's body weight, physical examination results, organ weight, and gross anatomy examination. Conclusions: This study presents the potential of secretome derived from MSCs as a safe immunomodulatory agent.
ISSN:2046-1402
2046-1402
DOI:10.12688/f1000research.131487.2